848 related articles for article (PubMed ID: 16707251)
1. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
2. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
Barcia JP
Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
[TBL] [Abstract][Full Text] [Related]
3. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
Drew R
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():36-44. PubMed ID: 16713192
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
5. Acrocyanosis developed with amphotericin B deoxycholate but not with amphotericin B lipid complex.
Ozaras R; Yemisen M; Mete B; Mert A; Ozturk R; Tabak F
Mycoses; 2007 May; 50(3):242. PubMed ID: 17472626
[No Abstract] [Full Text] [Related]
6. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
7. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?
Schneemann M; Bachli EB
Clin Infect Dis; 2004 Jan; 38(2):303-4; author reply 306-7. PubMed ID: 14699468
[No Abstract] [Full Text] [Related]
9. Estimating the true cost of amphotericin B.
Rex JH; Walsh TJ
Clin Infect Dis; 1999 Dec; 29(6):1408-10. PubMed ID: 10585787
[No Abstract] [Full Text] [Related]
10. Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation.
Mohr JF; Hall AC; Ericsson CD; Ostrosky-Zeichner L
Pharmacotherapy; 2005 Mar; 25(3):426-8. PubMed ID: 15843289
[TBL] [Abstract][Full Text] [Related]
11. Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate.
Garnacho-Montero J; Ortiz-Leyba C; García Garmendia JL; Jiménez Jiménez F
Clin Infect Dis; 1998 Apr; 26(4):1016. PubMed ID: 9564508
[No Abstract] [Full Text] [Related]
12. Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment.
Falci DR; dos Santos RP; Wirth F; Goldani LZ
Mycoses; 2011 Mar; 54(2):91-8. PubMed ID: 19878457
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.
Drew RH; Dodds Ashley E; Benjamin DK; Duane Davis R; Palmer SM; Perfect JR
Transplantation; 2004 Jan; 77(2):232-7. PubMed ID: 14742987
[TBL] [Abstract][Full Text] [Related]
14. Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs.
Krawiec DR; McKiernan BC; Twardock AR; Swenson CE; Itkin RJ; Johnson LR; Kurowsky LK; Marks CA
J Am Vet Med Assoc; 1996 Dec; 209(12):2073-5. PubMed ID: 8960189
[TBL] [Abstract][Full Text] [Related]
15. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
16. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations.
Winston DJ; Schiller GJ
Clin Infect Dis; 2000 Jan; 30(1):236-7. PubMed ID: 10619780
[No Abstract] [Full Text] [Related]
17. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
[TBL] [Abstract][Full Text] [Related]
18. Antifungals and renal safety--getting the balance right.
Saliba F
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():21-4. PubMed ID: 16704922
[TBL] [Abstract][Full Text] [Related]
19. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
20. Amphotericin B lipid complex (ABLC)-associated hypertension: case report and review.
Rowles DM; Fraser SL
Clin Infect Dis; 1999 Dec; 29(6):1564-5. PubMed ID: 10585814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
